HOUSE-WELLNESS-FOODS-CO
7.1.2020 13:47:07 CET | Business Wire | Press release
There’s a reason why the health-conscious focus has turned toward foods, supplements and behaviors to reduce inflammation. It’s why House Wellness Foods has put decades of meticulous research into the anti-inflammatory benefits of its unique immunobiotic Lactobacillus plantarum HK L-137 , the primary ingredient of its Immuno-LP20® . A just-published study illuminates how this bacillus, in its nonviable form, can be especially important, even lifesaving, to those contending with obesity.
Inflammation is a bodily response we rely on to counter stress, infection and external toxins. But we know that it is also one of the keystones of metabolic dysfunction. Many have gone as far as to suggest that inflammation is the defining characteristic of all infirmity, including the depredating aspects of the aging process itself, leading to eventual organ failure. Unchecked, it can cause the decline of overall health, is linked to a string of metabolic complications, and implicated in dozens of autoimmune diseases from lupus to MS.
Notably, even otherwise healthy individuals under the stress associated with high body mass can suffer a rapidly deteriorating downward spiral; and as we know, obesity is among the most prevalent disease factors in post-industrial society worldwide, (affecting about 40 percent of the U.S. population alone). Simply put, production of inflammatory cytokines increases in individuals carrying more body fat. Though the popular literature avoids the harsh details, the manifestation of this destructive cycle includes insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, hypertension, and dyslipidemia.
The new study from House Wellness Foods laboratories, in cooperation with the Medical Institute of Bioregulation, Kyushu University, describes in detail the process by which inflammation sets its destructive effects in motion. Adipose tissue produces an abundance of inflammatory cytokines, resulting in elevated serum levels of inflammatory mediators (C-reactive protein and leukocyte concentration among them). Tumor necrosis factor and interleukin induce systemic insulin resistance and affect lipid metabolism. There is a concomitant elevation of the serum levels of triglycerides and very-low-density lipoprotein (VLDL).
In the inflammation response, cells communicate via extraordinarily complex means to protect muscles and organs in bodies subjected to ordinary stress or injury. The research paper defines the consequences of lingering inflammation, such as that associated with overweight, and how the inflammatory mediators present in obese or overweight persons need to be suppressed to thwart associated metabolic disorders such as insulin resistance and hyperlipidemia.
Lactic acid-based bacterial probiotics have long shown effectiveness in immune modulation and lipid metabolism. Viable lactobacilli in foods like kefir and other probiotic boosters have proved valuable in lowering total cholesterol levels, but their effect is limited both by their chemistry and the mechanisms by which they act on the body. Multiple peer-reviewed studies have shown that nonviable bacilli, like (heat-killed) HK L-137, are equally, and in many instances more effective in improving obesity-induced inflammation and abnormalities of lipid metabolism, with a more profound impact on immune response as gauged by multiple measurements including enhanced Th1-related immune functions, such as concanavalin A (Con A)-induced proliferation in T cell production.
Heat-killing’s advantage is that it strengthens the bacterial organism’s cellular barriers and fixes its biogenetic material. It stands up to gastric fluids and remains intact through to the ileum of the small intestine, to go on to spur immune response in the mucosa. Heat-killing is what gives HK L-137, the prime constituent of House’s Immuno-LP20, its character as an immunobiotic, and as multiple peer-reviewed studies show, its cell protective and regenerative function supports quality of life improvements that include dramatic reduction of upper respiratory infection and periodontal disease. It also makes HK L-137 available for the widest range of applications due to its ability to withstand processing. Nonviability gives it an unparalleled shelf life without diminishing its effectiveness.
House Wellness Foods has devoted nearly 30 years to both the clinical study of the immunological and protective properties of HK L-137, and the refinement of its natural, food product-based production. The apex of its efforts is Immuno-LP20® , its functional immunobiotic based on HK L-137.
Metabolic syndrome is a crisis of global proportion. Countering it, House Wellness Foods, in its supplements and functional food products, has concentrated its focus on supporting the body’s innate ability to bolster immunity and restore vitality at the cellular level. It is a quest for nothing less than the sustenance of superior health and vigor, and the extension of all life on the planet.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005127/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
